Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer

We investigated the prognostic potential of pretherapy measurement of the neutrophil/lymphocyte ratio (NLR) in patients (n = 56) with non-small-cell lung cancer deemed suitable for treatment with nivolumab. This was a multicenter, noninterventional, retrospective data analysis, involving five oncolo...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer management 2020-07, Vol.9 (3)
Main Authors: Rapoport, Bernardo L, Theron, Annette J, Vorobiof, Daniel A, Langenhoven, Lizanne, Hall, Jacqueline M, Van Eeden, Ronwyn I, Smit, Teresa, Chan, Sze-Wai, Botha, Michael C, Raats, Johann I, Necker, Margriet De, Anderson, Ronald
Format: Article
Language:English
Subjects:
Antibodies
Biomarkers
Cancer therapies
Chemotherapy
Immunotherapy
Lung cancer
Lymphocytes
Medical prognosis
Metastasis
Monoclonal antibodies
neutrophil/lymphocyte ratio
Neutrophils
nivolumab
NSCLC
Patients
PD-1 inhibitor
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated the prognostic potential of pretherapy measurement of the neutrophil/lymphocyte ratio (NLR) in patients (n = 56) with non-small-cell lung cancer deemed suitable for treatment with nivolumab. This was a multicenter, noninterventional, retrospective data analysis, involving five oncology centers. Patients with prenivolumab NLR values of 2 metastatic sites had median OS values of 11.4 and 6.1 months, respectively (p = 0.0174). A Cox multiple regression model revealed baseline NLR ≥5 as the only variable significantly associated with decreased OS (p 
ISSN:1758-1966
1758-1974
DOI:10.2217/lmt-2020-0014